Interpharm Announces Voluntary AMEX Delisting

  
    
  
  
    
      Interpharm Holdings, Inc. (Amex: IPA) (“Interpharm”), 
      a manufacturer and distributor of generic pharmaceutical products, 
      announced today that it has notified the American Stock Exchange (the 
      "AMEX") that it intends to voluntarily withdraw its common stock, $0.01 
      par value (the "Common Stock"), from the AMEX listing and from the 
      registration under Section 12(b) of the Securities Exchange Act of 1934, 
      as amended (the “Act”) 
      because of liquidity issues which have caused Interpharm not to meet 
      listing standards of the AMEX. Interpharm is currently in the process of 
      selling all of its assets to a third party. Interpharm has not arranged 
      for listing or registration on another national securities exchange or 
      for quotation of the Common Stock in a quotation medium (as defined in 
      Rule 15c2-11 under the Act).
    
    
      About Interpharm Holdings, Inc.
    
    
      Interpharm currently develops, manufactures and distributes generic 
      prescription strength and over-the-counter pharmaceutical products. 
      Interpharm will continue to focus on growing organically through 
      internal product development and leveraging its strength in efficient 
      and cost effective manufacturing. In addition, Interpharm will also 
      continue to seek consummation of mutually beneficial strategic alliances 
      and collaborations.
    
    
      FORWARD-LOOKING STATEMENTS
    
    
      Statements made in this news release, contain forward-looking statements 
      concerning Interpharm's business and products involving risks and 
      uncertainties that could cause actual results to differ materially from 
      those reflected in the forward-looking statements. The actual results 
      may differ materially depending on a number of risk factors including, 
      but not limited to, the following: general economic and business 
      conditions, development, shipment, market acceptance, and additional 
      competition from existing and new competitors, changes in technology, 
      and various other factors beyond Interpharm's control. Other risks 
      inherent in Interpharm's business are set forth in its filings with the 
      SEC, including, but not limited to, its Form 10-K, filed on November 15, 
      2007, its Form 10-Q filed on December 12, 2007 and Form 10-Q filed on 
      February 15, 2008.
    
    
      All information in this release is as of April 22, 2008. Interpharm 
      undertakes no duty to update any forward-looking statements to conform 
      the release to actual results or changes in its circumstances or 
      expectations after the date of this release.